Skip to main content

Generics

  • FDA approves 3 Teligent topical generics
    SILVER SPRING, Md. — The Food and Drug Administration approved three generics from New Jersey-based specialty generics company Teligent on the last day of 2016, the company announced Tuesday. 
     
    The approvals were for the company’s generics of triamcinolone acetonide ointment, 1000,000 units/gram and 1mg/gram; clindamycin phosphate topical solution 1%; and flurandrenolide ointment, 0.05%. 
     

  • Walgreens expands availability of naloxone without a prescription

    DEERFIELD, Ill. — Walgreens has expanded the availability of prescription-free naloxone to 33 states and the District of Columbia.

    The medication can be dispensed in accordance with each state’s pharmacy regulations at nearly 5,800 Walgreens pharmacies. Naloxone can be used in the event of an overdose to reverse the effects of heroin or other opioid drugs, and is administered by injection or nasal spray.

  • Mylan launches generic EpiPen

    PITTSBURGH — Mylan on Friday introduced an authorized generic for EpiPen (epinephrine injection, USP) Auto-injector at a wholesale acquisition cost of $300 per injection. The product will reach pharmacies within approximately one week.

    According to Mylan, the generic is more than 50% lower than the wholesale acquisition cost of its EpiPen 2-Pak Auto-Injectors and has the same drug formulation and device functionality as its EpiPen Auto-Injector.

  • Lilly, Boehringer Ingelheim launch Lantus follow-on Basaglar
    INDIANAPOLIS and RIDGEFIELD, Conn. — Eli Lilly and Co. and Boehringer Ingelheim Pharmaceuticals on Thursday announced the launch and availability of their Basaglar. The drug is a follow-on insulin to U-100 insulin glargine Lantus and is a long-acting insulin with an amino acid sequence identical to that of Lantus. 
     

  • Alvogen, Natco launch first Tamiflu generic
    PINE BROOK, N.J.and HYDERABAD, India — Alvogen and Natco Pharma on Monday announced the launch of their generic of Tamiflu (oseltamivir phosphate) capsules, the first generic of the flu treatment to hit the U.S. market. The generic was approved by the Food and Drug Administration in August. 
     

  • Endo begins shipping first Zetia generic
    DUBLIN — Endo announced Thursday that its Par Pharmaceutical had begun shipping the first generic version of Zetia (ezetimibe) tablets. The drug is indicated to reduce elevated LDL cholesterol in patients with hyperlipidemia. 
     
    Par’s generic is entitled to market exclusivity based on the first-to-file status of the application filed by its licensing partners, Glenmark Pharmaceuticals USA. 
     

  • Sandoz launches generic Latisse
    PRINCETON, N.J. — Sandoz on Wednesday launched its generic of Allergan’s Latisse (bimatoprost ophthalmic solution, 0.03%) in the United States. The medication is indicated to treat hypotrichosis of the eyelashes by stimulating growth, length, thickness and darkness. 
     

  • Biotech stocks drop after Trump promises to ‘bring down drug prices’
    NEW YORK — Biotech stocks closed largely down on Tuesday, following a day of trading that began with a 2.5% drop in the SPDR S&P Biotech XBI index. The XBI closed down 4.02% and iShares Nasdaq Biotechnology ETF IBB closed down 2.94%. This is as the S&P closed up 1.32% and the Nasdaq closed up 1.14%. 
     
X
This ad will auto-close in 10 seconds